Madrigal Pharmaceuticals Announces Three Abstracts Accepted by The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting in November 2020, including Positive Data from Ongoing Open Label Arm of Resmetirom 52 Week Phase 3 MAESTRO-NAFLD-1 Trial
High accuracy in predicting advanced NASH fibrosis (F2-F3) in Phase 3 MAESTRO-NASH study using clinical characteristics and simple, readily available […]